Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-102 plus Bevacizumab Switch Maintenance in mCRC
NCT02654639Phase 2Terminated
- Sponsor
- Georgetown University
- Start
- Feb 2016
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trifluridine + tipiracil in metastatic colorectal cancer (mCRC), sponsored by Georgetown University. Started Feb 2016; status: terminated.
02
Drugs
trifluridine + tipiracil
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT02654639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02654639.